The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation
Abstract
BACKGROUND: Despite the excellent prognosis of Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage I, type I endometrial cancers, a substantial number of patients experience recurrence and die from this disease. We analyzed the value of immunohistochemical L1CAM determination to predict clinical outcome. METHODS: We conducted a retrospective multicenter cohort study to determine expression of L1CAM by immunohistochemistry in 1021 endometrial cancer specimens. The Kaplan-Meier method and Cox proportional hazard model were applied for survival and multivariable analyses. A machine-learning approach was used to validate variables for predicting recurrence and death. RESULTS: Of 1021 included cancers, 17.7% were rated L1CAM-positive. Of these L1CAM-positive cancers, 51.4% recurred during follow-up compared with 2.9% L1CAM-negative cancers. Patients bearing L1CAM-positive cancers had poorer disease-free and overall survival (two-sided Log-rank P < .001). Multivariable analyses revealed an increase in the likelihood of recurrence (hazard ratio [HR] = 16.33; 95% confidence interval [CI] = 10.55 to 25.28) and death (HR = 15.01; 95% CI = 9.28 to 24.26). In the L1CAM-negative cancers FIGO stage I subdivision, grading and risk assessment were irrelevant for predicting disease-free and overall survival. The prognostic relevance of these parameters was related strictly to L1CAM positivity. A classification and regression decision tree (CRT)identified L1CAM as the best variable for predicting recurrence (sensitivity = 0.74; specificity = 0.91) and death (sensitivity = 0.77; specificity = 0.89). CONCLUSIONS: To our knowledge, L1CAM has been shown to be the best-ever published prognostic factor in FIGO stage I, type I endometrial cancers and shows clear superiority over the standardly used multifactor risk score. L1CAM expression in type I cancers indicates the need for adjuvant treatment. This adhesion molecule might serve as a treatment target for the fully humanized anti-L1CAM antibody currently under development for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Cited by
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
Stelloo, E., Nout, R. A., Osse, E. M., Jürgenliemk-Schulz, I. J., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 846
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000609 · Cited by 767
Self-citationEndometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652
Self-citationAmant, F., Mirza, M. R., Koskas, M., & Creutzberg, C. L. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12612 · Cited by 356
Self-citation
Metadata
- Authors
- Zeimet, A. G., Reimer, D., Huszar, M., Winterhoff, B., Puistola, U., Abdel Azim, S., Müller-Holzner, E., Ben-Arie, A., van Kempen, L. C., Petru, E., Jahn, S., Geels, Y. P., Massuger, L. F., Amant, F., Polterauer, S., Lappi-Blanco, E., Bulten, J., Meuter, A., Tanouye, S., Oppelt, P., Stroh-Weigert, M., Reinthaller, A., Mariani, A., Hackl, W., Netzer, M., Schirmer, U., Vergote, I., Altevogt, P., Marth, C., & Fogel, M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-18
- Volume
- 105
- Issue
- 15
- Pages
- 1142-1150
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2161471989
- Cited by
- 226
- References
- 2
- FWCI
- 20.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. https://app.cochat.ai/papers/10.1093/jnci/djt144
- The paper
- Zeimet, A. G., Reimer, D., Huszar, M., Winterhoff, B., Puistola, U., Abdel Azim, S., Müller-Holzner, E., Ben-Arie, A., van Kempen, L. C., Petru, E., Jahn, S., Geels, Y. P., Massuger, L. F., Amant, F., Polterauer, S., Lappi-Blanco, E., Bulten, J., Meuter, A., Tanouye, S., . . . Fogel, M. (2013). L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.